It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Research analysts at HC Wainwright reduced their FY2024 earnings ...

Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for ...

With full confidence in China, where Novartis recorded 17 percent growth last year, one of the fastest among all major ...

SG&A expenses were $122.0 million for the third quarter of 2024, compared to $145.7 million for the same period in 2023. The decrease was primarily attributable to decreases in personnel related costs ...